Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04552288 · ClinicalTrials.gov registry record · Phase 2
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
A Phase 2 study of Solid Tumor and Solid Tumor, Adult, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 5
- Study locations
NCT04552288: Active Phase 2 study of Solid Tumor and Solid Tumor, Adult, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04552288 is a Phase 2 study of Solid Tumor and Solid Tumor, Adult that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 51 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (77% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04552288, a Phase 2 study of Solid Tumor and Solid Tumor, Adult, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood. Reducing the skin side effects of your cancer treatment may improve quality of life and allow participants to continue to receive their usual cancer treatment.
Primary Outcome
To evaluate the percent reduction in CTCAE grade 2/3 eosinophil-related cutaneous adverse events to grade ≤1 resulting from checkpoint inhibitors (CPIs) or targeted therapies with absolute blood eosinophil counts of at least .3 K/mcl.
Conditions Studied
Interventions
- DRUG Benralizumab
Study Locations (5)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (Limited Protocol Activities) - Hauppauge
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
New Jersey
- Memorial Sloan Kettering Cancer Center - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2020-09-16 |
| Est. Completion | 2026-03-16 |
| Phase | Phase 2 |
What the registry record for NCT04552288 still lists
NCT04552288 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (77% lower).
The record links to 4 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Benralizumab is the first listed.
NCT04552288 lists 5 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT04552288 about?
NCT04552288 is a clinical study titled "Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies". The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood. Reducing the skin side effects of your cancer treatment may improve quality of life an...
What is the current status of trial NCT04552288?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2020-09-16. Estimated completion is 2026-03-16.
What conditions does trial NCT04552288 study?
This clinical trial studies the following conditions: Solid Tumor, Solid Tumor, Adult, Hematologic Malignancy, Solid Carcinoma.
What interventions are being tested in trial NCT04552288?
The interventions under investigation include: Benralizumab (DRUG).
Who is sponsoring clinical trial NCT04552288?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04552288 being conducted?
This trial has 5 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04552288's enrollment target sits among peer trials
51 120th of 196 higher than 76 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
RECRUITING · Phase 2
-
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
RECRUITING · Phase 2
-
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI